Therefore, the presence of patients with AD having comorbid anxiety/depressive disorders in a study group may be an important factor influencing findings of DAT availability, but previous brain imaging studies could not exclude these confounding factors [7–9, 28]. This evidence concerns the gene SLC6A3 and Alzheimer disease.